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Insulin-like growth factor-I (IGF-I) stimulates vascular
smooth muscle cell proliferation and migration by activating
bothMAPK and phosphatidylinositol 3-kinase (PI3K). Vascular
smoothmuscle cells (VSMCs)maintained in 25mM glucose sus-
tain MAPK activation via increased Shc phosphorylation and
Grb2 association resulting in an enhanced mitogenic response
compared with cells grown in 5 mM glucose. PI3K plays a major
role in IGF-I-stimulated VSMC migration, and hyperglycemia
augments this response. In contrast toMAPKactivation the role
of Shc in modulating PI3K in response to IGF-I has not been
determined. In this studywe show that impaired Shc association
with Grb2 results in decreased Grb2-p85 association, SHPS-1-
p85 recruitment, and PI3K activation in response to IGF-I.
Exposure of VSMCs to cell-permeable peptides, which con-
tained polyproline sequences from p85 proposed to mediate
Grb2 association, resulted in inhibition of Grb2-p85 binding
andAKT phosphorylation. Transfected cells that expressed p85
mutant that had specific prolines mutated to alanines resulted
in less Grb2-p85 association, and a Grb2 mutant (W36A/
W193A) that attenuated p85 binding showed decreased associ-
ation of p85 with SHPS-1, PI3K activation, AKT phosphoryla-
tion, cell proliferation, and migration in response to IGF-I.
Cellular exposure to 25 mM glucose, which is required for Shc
phosphorylation in response to IGF-I, resulted in enhanced
Grb2 binding to p85, activation of PI3K activity, and increased
AKT phosphorylation as compared with cells exposed to 5 mM
glucose.We conclude that inVSMCs exposed to hyperglycemia,
IGF-I stimulation of Shc facilitates the transfer of Grb2 to p85
resulting in enhanced PI3K activation and AKT phosphoryla-
tion leading to enhanced cell proliferation and migration.
Insulin-like growth factor-I (IGF-I)2 stimulates proliferation
and migration in vascular smooth muscle cells (VSMCs) (1).
IGF-I-stimulated VSMC migration and/or proliferation
requires ligand occupancy of the V3 integrin (2). Activation
of the IGF-I receptor is coupled to downstream signaling events
via recruitment and phosphorylation of twomajor adaptor pro-
teins, Shc or members of the insulin receptor substrate (IRS)
family. In VSMCs IGF-I stimulation leads to recruitment of the
signaling protein Shc to SHP substrate-1 (SHPS-1) allowing
sustained MAPK activation (3). IGF-I stimulation of phospha-
tidylinositol 3-kinase (PI3K) is also required to induce VSMC
migration (4). Hyperglycemia has been shown to increase the
responsiveness of smoothmuscle cells as well as other cell types
to growth factor stimulation (5–9). Following IGF-I stimulation
of porcine VSMCs maintained in hyperglycemic conditions
(e.g. 12 mM glucose) there is an increase in Shc phosphoryla-
tion and subsequent Grb2 association resulting in sustained
MAPK activation and enhanced cell proliferation. In contrast
cells grown in 5 mM glucose do not show these changes (5).
Mutation of three Shc tyrosine phosphorylation sites, Tyr-239/
240/317, that are required for Grb2 association to phenylala-
nine (Shc-3F) generates a dominant negative inhibitor of Shc
signaling leading to attenuatedMAPKactivation (10–13). Inhi-
bition of Shc signaling by expressing this mutant form
decreases the mitogenic response to IGF-I (3).
PI3Ks are a family of enzymes that catalyze the phosphoryl-
ation of the 3-position of the inositol ring in the phosphoinosit-
ide 4,5-bisphosphate to yield phosphatidylinositol 3,4,5-
trisphosphate that functions to recruit downstream signaling
molecules such as AKT to the cell membrane (14). The class IA
PI3Ks contain two subunits: the p110 catalytic subunit that
contains the enzymatic activity and p85, the regulatory adap-
tor subunit. The p85 subunit plays an important role in medi-
ating the activation of p110 in response to tyrosine kinases.
These tyrosine kinases may be an integral part of a receptor
such as growth factor receptors (e.g. platelet-derived growth
factor and epidermal growth factor), or they can be nonrecep-
tor tyrosine kinases that either associatewith or are activated by
receptors (e.g. Syk and ZAP70) or the Src family of protein-
tyrosine kinases that associate with B cell or T cell receptors.
These tyrosine kinases phosphorylate the critical tyrosine resi-
dues within activation motifs that can be present on the recep-
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tors themselves (e.g. platelet-derived growth factor or Fc recep-
tors) or present on the receptor-associated proteins, termed
adaptors (e.g. IRS-1, Gab, and Cbl). These phosphotyrosine res-
idues then act as binding sites for specific SH2 domain-contain-
ing effector molecules (15). The SH2 domain of p85 binds to
phosphotyrosine residues contained in the sequence pYXXM
(where pY is phosphotyrosine) on receptor tyrosine kinases or
adaptor molecules such as IRS-1 (16). This binding relieves
both the basal inhibition of p110 by p85 and recruits the p85-
p110 heterodimer to the plasmamembrane (17) where it phos-
phorylates phosphoinositide 4,5-bisphosphate generating
phosphatidylinositol 3,4,5-trisphosphate (18). In addition p85
can interact with other adaptors such as Gab2 that function to
recruit the p85p110 complex to the plasma membrane (18),
resulting in an increase in the PI3K enzymatic activity. Various
proteins that contain SH3 domains (e.g. Lyn, Fyn, Abl, and Lck)
have been shown to bind to the proline-rich region of p85 (19)
and activate PI3K (20). Activation of BaF3 cells by interleukin 3
recruits p85 to the plasma membrane via a complex scaffold
formed by three adaptor proteins, Shc, Grb2, and Gab2, and
formation of this complex results in PI 3-kinase activation (21).
Thus, the recruitment and activation of PI3K can be accom-
plished by multiple distinct pathways.
In most cell types IGF-I activation of PI3K is dependent on
phosphorylation of the adaptor protein IRS-1 that subsequently
associates with p85 and functions to recruit the p85p110
complex to the cell membrane. However, hyperglycemia
reduces tyrosine phosphorylation of IRS-1 (5), and IRS-1-me-
diated PI 3-kinase/AKT activation has been shown to be down-
regulated in several cell types in hyperglycemic conditions (8,
22–25). Because hyperglycemia has been shown to enhance the
ability of IGF-I to stimulate Shc activation and cell migration,
this study was undertaken to determine whether Shc activation
and subsequent Shc-Grb2 association played a role in PI3K
activation and whether Grb2 association with p85 was required
for IGF-I-stimulated cell migration.
MATERIALS AND METHODS
Human IGF-I was a gift from Genentech (South San Fran-
cisco, CA). Immobilon-P membranes were purchased from
Millipore Corp. (Bedford, MA). DMEM containing 4500 mg of
glucose/liter (DMEM-HG) or DMEM containing 900 mg of
glucose/liter (DMEM-NG) was purchased from Invitrogen.
Streptomycin and penicillin were purchased from Invitrogen.
Antibodies against phospho-AKT, total AKT, and -actin were
from Cell Signaling Technology Inc. (Beverly, MA). Polyclonal
antibodies for the p85 subunit and Shc were obtained from
Upstate Biotechnology (Lake Placid, NY). Anti-phosphoty-
rosine (PY 99), the hemagglutinin (HA) epitope, and anti-Grb2
antibodies were purchased from Santa Cruz Biotechnology,
Inc. (Santa Cruz, CA). SHPS-1 polyclonal antiserum was pre-
pared in our laboratory (26). The horseradish peroxidase-con-
jugated mouse anti-rabbit, goat anti-mouse, and mouse anti-
rabbit light chain-specific antibodies were purchased from
Jackson ImmunoResearch Laboratories (West Grove, PA).
Phosphatidylinositol substrate and the control lipid L--phos-
phatidylinositol 4-phosphate were purchased from Avanti
Polar Lipids (Alabaster, AL). Unlabeled ATP was purchased
from Sigma, and [-32P]ATP was from GE Healthcare. Two
synthetic peptides containing the protein transduction domain
4 (27) and one of two proline-rich regions of the p85 subunit,
YARAAARQARA82SPPTPKPRPPRPLPV97 (underlined and
hereafter referred to as peptide 264) and YARAAARQARA300-
ERQPAPALPPKPPKPT315 (underlined and hereafter referred
to as peptide 265), were synthesized by the Protein Chemistry
Core Facility at the University of North Carolina at Chapel Hill.
Purity and sequence confirmation were determined by mass
spectrometry.
Cell Culture—Porcine VSMCs were isolated from the por-
cine aortic explants and were maintained as described previ-
ously (28). Cells were maintained in DMEM-high glucose (25
mM) growth medium (referred to as HG) or DMEM-normal
glucose (5 mM) growth medium (referred to as NG) with 10%
fetal bovine serum (Hyclone, Logan, UT) and 100 g/ml strep-
tomycin and 100 units/ml penicillin. Both media were supple-
mented with 1.0 mM pyruvate. Cultured VSMCs were used
between passages 4 and 12.
Generation of pLenti Expression Vectors pLenti-HA-p52Shc/
Wild Type (Shc-WT) and pLenti-HA-p52Shc/3F (Shc-3F)—
pcDNA-p52Shc/WT and pcDNA-p52Shc/3F (Shc/Y239F/
Y240F/Y317F) constructs were kindly provided byDr. Kenneth
Yamada (National Institutes of Health, Bethesda, MD). Muta-
tion of these three tyrosine phosphorylation sites has been
shown to generate a dominant negative inhibitor of Shc signal-
ing (29). The full-length Shc-WT and Shc-3F cDNAs were pre-
pared and ligated into the pLenti vector as described previously
(3). Similarly VSMCs expressing these cDNAswere prepared as
described previously (3).
pLenti-HA-p85 Wild Type (p85-WT), pLenti-HA-p85
Mutant Proline Region 1 (p85-P1), and pLenti-HA-p85
Mutant Proline Region 2 (p85-P2)—Human p85 DNA was
obtained by PCR using first strand cDNA transcribed from
HepG2 cell total RNA. The full-length p85 wild type was
cloned into the expression vector pLenti-6DV5 using TOPO
methodology as reported previously (30). Using 100 ng of
pLenti-p85 wild type as template, PCR amplification was car-
ried out with forward primer 5-caccatgagtgctgaggggtaccagt-
aca-3 and reverse primer 5-ttaagcgtaatctggaacatcgtatgggtat-
cgcctctgctgtgcatatactgggta-3. The forward primer includes a
Kozak sequence (in bold) followedby theATGstart site (under-
lined). The reverse primer contains the sequence encoding HA
epitope (underlined) followed by the stop codon (in bold). The
PCR product was cloned into the pENTR/D-TOPO Gateway
vector according to the manufacturer’s instructions (Invitro-
gen). The complete sequence was verified by DNA sequencing
(University of North Carolina Genome Analysis Facility,
Chapel Hill, NC). Two independent mutants were made. In
each mutant four prolines within p85 were mutated to ala-
nines. For generating the first proline region mutant (p85-P1),
prolines at positions 84, 87, 91, and 94 were mutated to alanine
by double-stranded mutagenesis using the pENTRp85-WT as
template. Two hundred nanograms of pENTRp85-WT was
amplified by PCR using Pfx polymerase and complimentary
primers (Invitrogen). The sequence of the forward primer was
5-attggaaggaaaaaaatctcgGctcccacaGcaaagccccggGcacctcgg-
Gctcttcctgttgcaccag-3, and the reverse primer was 5-ctggtgc-
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aacaggaagagCccgaggtgCccggggctttgCtgtgggagCcgagatttttttcc-
ttccaat-3 where the capitalized bases indicate the substitutions.
Similarly for generating the second proline region mutant
(p85-P2), the prolines at positions 305, 308, 311, and 314
were mutated to alanine using the pENTRp85-WT as tem-
plate. Two complimentary primers, forward primer 5-
gaatgaacgacagcctgcaGcagcactgGctcctaaaGcaccaaaaGctactact-
gtagccaacaacg-3 and reverse primer 5-cgttgttggctacagtagtag-
CttttggtgCtttaggagCcagtgctgCtgcaggctgtcgttcattc-3wereused to
generate the p85-P2 mutant. The capitalized bases indicate the
substitutions. The mutant products were also sequenced to con-
firmthecorrect incorporationof thechangesand transferred from
the entry vector into pLentiCMVDEST vector (Invitrogen) using
theLRClonase reaction following themanufacturer’s instructions
(Invitrogen).
pLenti-Grb2 Wild Type (Grb2-WT) and pLenti-Grb2-WA
Mutant—Full-length porcine Grb2 was generated using first
strand cDNA transcribed from porcine vascular smooth mus-
cle cell total RNA and cloned into the pENTR/D-TOPO Gate-
way entry vector according to the manufacturer’s instructions
(Invitrogen). The forward and reverse primers used to generate
the PCR product were: forward primer, 5-caccatggaagccatcg-
ccaaatatgac-3; and reverse primer, 5-ttaagcgtaatctggaacatcg-
tatgggtagacgttccggttcacgggggtgac-3. The forward primer
includes a Kozak sequence (bold) placed 5 to the ATG (under-
lined) start site. The reverse primer contained the sequence
encoding HA epitope (underlined) followed by the stop codon
(bold). Using the pENTRGrb2-WT as template, the trypto-
phans at positions 36 and 193 were mutated to alanine (Grb2-
WA) by double-stranded mutagenesis. PCR amplification was
carried out using forward primer 5-ttgaatgaagaatgtgatcagaac-
GCgtacaaagcagagctcaatg-3 and reverse primer 5-cattgagctct-
gctttgtacGCgttctgatcacattcttcattcaa-3 where capitalized bases
indicate the substitution W36A. Using the product with
mutant W36A as template a second PCR was performed using
forward primer 5-ggataactcggaccccaacGCgtggaagggggct-
tgc-3 and reverse primer 5-gcaagccccttccacGCgttggggtcc-
gagttatcc-3 where the capitalized bases indicate the substitution
W193A.After selectionof correct clonesbasedon sequencing, the
cDNAs encoding the wild type and mutant protein were trans-
ferred from the entry vector into pLentiCMV DEST vector using
theLRClonase reaction following themanufacturer’s instructions
(Invitrogen).
Generation of Virus Stocks—293FT cells (Invitrogen) were
prepared for generation of virus stocks of each individual
pLenti construct. Cells were plated at 5  106/75-cm2 plate
(CorningGlassworks, Corning, NY) the day before transfection
in the growth medium (DMEM-HG with 10% FBS, 100 g/ml
streptomycin, and 100 units/ml penicillin). On the day of trans-
fection, the culture medium was replaced with 5 ml of Opti-
MEM I (Invitrogen) without antibiotics or serum.
DNALipofectamine 2000 complexes for each transfection
were prepared according to the manufacturer’s protocol
(Invitrogen). The next day, the medium containing the
DNALipofectamine 2000 complexes was removed and
replacedwith the growthmedium. The virus-containing super-
natants were harvested 48–72 h post-transfection and centri-
fuged at 3000 rpm for 15min at 4 °C to pellet the cell debris. The
supernatants were filtered and stored as 1-ml aliquots at
80 °C.
Establishment of Porcine VSMCs Expressing pLenti
Constructs—VSMCs (passage 4–5) were seeded at 3 105/well
in each of two wells of a 6-well plate (Falcon catalog number
353046) the day before transduction. The viral stocks were
thawed, and the viral complexes were precipitated as described
previously (3). For transduction, the pelletwas resuspended in 1
ml of growthmedium, 1l of Polybrene (40mg/ml) was added,
and the mixture was incubated with the cells for 24 h. The
virus-containing medium was removed and changed to 2 ml of
growth medium for another 24 h and then replaced with selec-
tion medium (growth medium containing 4 g/ml blasticidin).
The cultures were then grown to confluency and expanded for
experiments or frozen for subsequent experiments. VSMCs
expressing all the pLenti constructs and the nontransduced
VSMCs used for peptide experiments were maintained in
DMEM-HG. The expression of the HA-tagged Shc-WT, Shc-
3F, p85-WT, p85-P1 and p85-P2 mutants, Grb2-WT, and
Grb2-WA mutant were detected by immunoblotting using a
1:1000 dilution of anti-HA antibody and 30 l of cell lysate.
Immunoprecipitation and Immunoblotting—Cells were
seeded at 5  105 cells/10-cm plates (Discovery Labware) and
then grown for 5 days to reach confluency. The cultures were
incubated in serum-free DMEM-HG or DMEM-NG for 14–18
h before the addition of IGF-I (as indicated). In some experi-
ments, nontransduced VSMCs were preincubated with or
without the synthetic peptides that contained a region of
sequence from p85 for 1 h before IGF-I was added. Similarly for
experiments comparing the effect of glucose, nontransduced
VSMCs that had been grown in HG or NG were placed in
serum-free DMEM with the respective glucose concentration
prior to initiation of the experiment. The VSMCs grown in NG
were supplemented to 25 mM mannitol to control for differ-
ences in osmolarity. The cellmonolayerswere lysed inmodified
radioimmunoprecipitation assay (RIPA) buffer (1% Nonidet
P-40, 0.25% sodium deoxycholate, 1 mM EGTA, 150 mM NaCl,
and 50mMTris-HCl (pH7.5)) in the presence of protease inhib-
itors (10 g/ml aprotinin, 1 g/ml leupeptin, 1 mM phenyl-
methylsulfonyl fluoride, and 1 g/ml pepstatin) and phospha-
tase inhibitors (25 mM sodium fluoride and 2 mM sodium
orthovanadate). The cell lysates were centrifuged at 14,000  g
for 10 min at 4 °C. The supernatants containing crude mem-
brane and cytosolic proteins were exposed to a 1:300 dilution of
anti-Grb2, anti-HA, anti-SHPS-1, or anti-p85 antibody over-
night at 4 °C. The immunoprecipitates were immobilized using
protein A-Sepharose beads for 2 h at 4 °C and washed three
times with the same lysis buffer. The precipitated proteins were
eluted in 40 l of 2 Laemmli sample buffer, boiled for 5 min,
and separated by 8 or 11% SDS-PAGE. The proteins were then
transferred to Immobilon-Pmembranes that had been blocked
for 2 h in 5% milk or 3% bovine serum albumin in Tris-saline
buffer with 0.2%Tween 20. The blots were incubated overnight
at 4 °C with the antibody indicated (1:1000 for Tyr(P) mouse)
and 1:1000 for anti-HA (rabbit), -Grb2 (mouse), -p85 (rabbit),
-SHPS-1 (rabbit), or -Shc (mouse)). To detect phospho-AKT,
15g of protein from the cell lysate was removed before immu-
noprecipitation, mixed with 2 Laemmli sample buffer, and
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then separated by SDS-PAGE. Anti-phospho-AKT (Ser-473,
Thr-308) (1:1000) was used to detect phosphorylated AKT, and
total AKT protein was detected using an anti-AKT antibody
(1:1000). The immune complexes were detected using either an
anti-mouse (1:10,000) or anti-rabbit (1:20,000) horseradish
peroxidase-conjugated antibody and developed with enhanced
chemiluminescence following the manufacturer’s instructions
(Pierce). The images obtained were also scanned using a
DuoScan scanning densitometer (Agfa, Morstel, Belgium).
Densitometric analyses of the images were determined using
National Institutes of Health ImageJ, 1.37v. To determine dif-
ferences in AKT phosphorylation, arbitrary scanning units
obtained for phospho-AKT band intensities were divided by
arbitrary scanning units obtained for total AKT or -actin pro-
tein band intensities for each time point analyzed. The average
values obtained from at least three independent experiments
for each variable were pooled.
PI 3-Kinase Assay—The confluent VSMC cultures were
maintained in 0.2% FBS overnight and stimulated with IGF-I
(50 or 100 ng/ml) for 10 min before cells were lysed. The cell
lysates were prepared, and the PI 3-kinase complexes were
immunoprecipitated as described above for immunoprecipita-
tion of p85 or Grb2. The PI 3-kinase assay was performed as
described previously (30). Briefly the p85 or Grb2 immunopre-
cipitates were washed once with phosphate-buffered saline,
twice with lysis buffer, and once with the reaction buffer and
resuspended in 50 l of the reaction buffer (31). The reaction
was initiated by addition of 25 l of ATP mixture containing
440 mM cold ATP, 30 Ci of [-32P]ATP (GE Healthcare), and
20 g of phosphatidylinositol (PI3K) substrate with 100 mM
MgCl2 and then incubated for 10min at 22 °C, and the reaction
was stopped with addition of 20 l of 8 N HCl. Then 160 l of
chloroform/methanol (1:1) was added to extract the lipid prod-
uct from the reaction mixture, and the organic phase was spot-
ted onto a thin layer chromatography plate (catalog number
05-713-318, Fischer Scientific) impregnatedwith 1% potassium
oxylate and resolved by ascending chromatography (CHCl3:
CH3OH:H2O:NH4OH at 60:47:11.3:2). The plates were dried,
and the lipid products were identified by phosphorimaging
and/or autoradiography. The radiolabeled PI3K spots were
scraped, and the amount of radioactivity was quantitated by
Cherenkov counting using a Beckman LS6500 scintillation
counter.
Cell Proliferation—Assessment of VSMC proliferation was
performed as described previously (32). Briefly VSMCs were
plated at 3  104 cells/well in 24-well plates in serum-free
medium containing 2% FBS and incubated overnight. The cul-
tures were washed and then incubated in serum-free DMEM
containing 0.2% platelet-poor plasma with or without IGF-I
(50 ng/ml) for 48 h. Cell number in each well was counted
after trypsinization. Each treatment was analyzed in tripli-
cate. The results represent mean values of three independent
experiments.
CellWounding andMigration Assay—VSMCswere plated in
6-well dishes and grown to confluence. A monolayer of cells
was wounded with a razor blade as described previously (33).
After wounding, cells were rinsed twice in serum-free medium
and incubated in serum-freemedium containing 0.2% FBSwith
or without IGF-I at 100 ng/ml for 48 h at 37 °C. The cells were
then fixed and stained (Diff-Quick, Dade Behring Inc., Newark,
DE), and the number of cells thatmigrated at least 5minto the
wound area was counted. At least five of the 10 previously
selected 1-mm areas at the edge of the wound were counted for
each data point. Each experiment was repeated three times.
Statistical Analysis—Student’s t test or the analysis of vari-
ance was used to compare the differences between the treat-
ments as appropriate. The results that are shown in all experi-
ments are representative of at least three separate experiments.
p  0.05 was considered statistically significant.
RESULTS
Inhibition of Shc Phosphorylation Impairs PI 3-Kinase Acti-
vation and Downstream Signaling—Previously we showed that
Shc phosphorylation was required for an optimal mitogenic
response to IGF-I in VSMCs maintained in 25 mM glucose and
that expression of a p52Shcmutant, Y239F/Y240F/Y317F (Shc-
3F), inhibited IGF-I-stimulated mitogen-activated protein
kinase activation and cell proliferation (3). Because cell prolif-
eration is decreased in VSMCs expressing the Shc-3F mutant
andPI3K activation is required for optimal cell proliferation,we
wished to determine whether attenuation of Shc activation
would alter the ability of IGF-I to activate PI3K. Therefore we
compared VSMCs that expressed wild type Shc (Shc-WT) to
cells expressing the Shc-3F mutant that were maintained in 25
mM glucose. Control experiments showed that the cells
expressing the Shc-3F mutant had reduced tyrosine phospho-
rylation andShc-Grb2 association comparedwith cells express-
ing Shc-WT (Fig. 1A). Because it had been shown that Grb2
binding to p85 could alter PI3K activation in vitro (34) we
wished to determine whether IGF-I stimulated Grb2-p85 asso-
ciation. Grb2-p85 associationwas increased 4.3 0.6-fold (n
4, p  0.05) in the cells expressing wild type Shc in response to
IGF-I. Phosphorylated Shc binds to Grb2; therefore, we next
determined whether disrupting Shc-Grb2 would result in dis-
ruption of Grb2-p85. In contrast to cells expressing Shc-WT,
following IGF-I addition there was no change in the association
of Grb2 with p85 in the cells expressing Shc-3F (Fig. 1A).
Because we previously demonstrated that Shc recruitment to
plasma membrane protein SHPS-1 is necessary for IGF-I-de-
pendent Shc phosphorylation (3), we wished to investigate the
role of Shc in recruitment of Grb2-associated p85 to SHPS-1.
Following the IGF-I stimulation, recruitment of p85 to SHPS-1
was significantly increased 3.1  0.4-fold (n  4, p  0.05) in
the Shc-WT cells compared with nonstimulated cells, whereas
the IGF-I had no effect on the Shc-3F mutant cells (Fig. 1A).
To ascertain the consequences of Grb2-p85 disruption we
examined PI3K activation and activation of its downstream
mediator AKT. In response to IGF-I, cells expressing Shc-WT
showed a 2.3  0.1-fold (n  3, p  0.05) greater increase in
AKT Ser-473 phosphorylation compared with cells expressing
Shc-3F. Similarly stimulation of Thr-308 was increased to a
level that was 2.1 0.1-fold (n 3, p 0.01) greater than in the
Shc-3F cells (Fig. 1B). p85-associated PI 3-kinase activity
increased 2.8  0.1-fold in Shc-WT cells in response to IGF-I
stimulation, but the Shc-3F-expressing cells showed almost no
increase (1.6  0.1-fold) in PI 3-kinase activity in response to
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IGF-I (Fig. 1C). To determine whether the Grb2p85 complex
showed similar differences in PI 3-kinase activity we immuno-
precipitated Grb2 and directly measured PI 3-kinase. Immuno-
precipitation of Grb2 followed by quantitation of PI 3-kinase
activity showed a 4.9  0.4-fold increase (n  3, p  0.001) in
the Shc-WT cells, whereas the cells expressing the Shc-3F
mutant showed only a 1.9  0.6-fold rise in activity. This 2.5 
0.2-fold difference between the two cell types was significant
(p  0.05) (Fig. 1D). Because our prior studies had shown that
PI 3-kinase activation was required for IGF-I to stimulate cell
migration (4) we compared migra-
tion in the two cell types. The
Shc-3F cells showed no significant
change in response to IGF-I,
whereas the Shc-WT cells showed a
2.9  0.1-fold increase (p  0.001)
(Fig. 1E).
Disrupting p85-Grb2 Association
Leads to Attenuation of PI 3-Kinase
and AKT Activation—Direct asso-
ciation of the SH3 domain of Grb2
with the polyproline region of the
p85 subunit of p85 kinase has been
demonstrated in vitro (Fig. 2A) (34).
To determine whether disrupting
Grb2-p85 would alter AKT activa-
tion we used cell-permeable pep-
tides containing each of the two
polyproline regions that mediate
Grb2 binding. Smooth muscle cells
exposed to each of the cell-perme-
able peptides (peptides 264 and 265)
showed significant impairment of
Grb2-p85 association in response to
IGF-I (Fig. 2A).
Exposure to peptide 264 de-
creased the association of Grb2 and
p85 by 1.5  0.3-fold (p  0.05),
peptide 265 inhibited it by 2.5 0.2-
fold (p 0.01), and the combination
resulted in greater inhibition (3.4 
0.2-fold; p  0.01) (Fig. 2B). Quan-
titation showed that peptide 265
had a slightly greater effect on dis-
rupting this association as com-
pared with peptide 264 (p  0.01).
The combination of both peptides
at a low concentration (i.e. 5 g/ml)
demonstrated an additive effect.
When IGF-I stimulation of phos-
phorylation of AKT Thr-308 was
examined, there was a significant
decrease with either peptide 264
(e.g. 1.4 0.2-fold; p 0.05) or with
peptide 265 (1.8  0.1-fold; p 
0.05). The combination of both pep-
tides had a significantly greater
inhibitory effect (2.7 0.1-fold; n
3, p  0.001). The ability of the peptides to inhibit Ser-473
phosphorylationwas significant (p 0.05) but less than that for
Thr-308 (1.4-, 1.6-, and 2.1-fold decreases) (Fig. 2B). Because
incubation with peptides decreased Grb2-p85 association and
AKT phosphorylation that is required for IGF-I-induced cellu-
lar functions, we compared proliferation and migration of
VSMCs maintained in DMEM-HG with or without peptides
264 and 265 independently or when added together. Cellular
proliferation was increased after IGF-I stimulation 2.3  0.2-
fold (p  0.01, n  4). In contrast in the presence of both the
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peptides cell number was unchanged 1.1  0.1-fold (p not sig-
nificant, n  4) (Fig. 2C). Similarly each peptide alone signifi-
cantly inhibited the proliferation response (data not shown).
Cellularmigrationwas also disrupted by blocking theGrb2-p85
association with the peptides. Cell migration was increased
2.4  0.3-fold (p  0.01, n  3) after IGF-I stimulation com-
pared with nonstimulated cells. In contrast in the presence of
both peptidesmigration was increased 1.4 0.1-fold (p 0.05,
n  3) compared with the response without peptide addition
(Fig. 2D). These results clearly demonstrate that disruption of
Grb2-p85 binding by the peptides attenuated VSMC prolifera-
tion and migration.
To more definitively determine the role of Grb2 association
with p85 in regulating PI3K activity, we prepared cells that
expressedmutant forms of p85 inwhich each of the polyproline
regions was mutated to alanine. Immunoblotting for HA
showed that cells expressing the wild type p85 or p85 mutants
had equivalent expression (Fig. 3A). Immunoprecipitation with
an anti-Grb2 antibody followed by immunoblotting for p85
revealed that IGF-I stimulated an increase in Grb2-p85 associ-
ation (e.g. 3.2  0.4-fold; n  4, p  0.05) in cells expressing
p85-WT (Fig. 3B). When cells expressing the P1 site mutant
were analyzed for Grb2-p85 association the degree of increase
was attenuated 2.2  0.1-fold compared with p85-WT cells
(p  0.05). When the cells expressing the P2 mutant were
examined there was also a significant attenuation 2.9 0.2-fold
compared with p85-WT cells (p  0.01) (Fig. 3B). In the cells
expressing an empty vector the amount of Grb2-p85 associa-
tion was comparable to the p85-WT cells (data not shown).
Importantly the ability of IGF-I to stimulate PI 3-kinase activa-
tion was significantly impaired in the cells expressing the
p85-P1 mutant. The increase in p85-associated PI 3-kinase
activity was 3.8  0.3-fold above basal in the cells expressing
p85-WT, whereas those expressing the P1 mutant showed a
1.4  0.1-fold increase that was not significant (Fig. 3C). Con-
sistent with this result, when we measured AKT Ser-473 and
Thr-308 phosphorylation (Fig. 3B), both were markedly inhib-
ited in the cells expressing the P1 mutant form of p85 as com-
pared with those expressing the p85-WT. IGF-I stimulated a
36.7 1.1-fold increase inAKTThr-308 phosphorylation and a
32.4  1.1-fold change in AKT Ser-473 phosphorylation in the
p85-WT-expressing cells. In contrast the response of the cells
expressing the P1 mutant was 10.3  0.5-fold for Ser-473 and
4.5  0.1-fold for Thr-308. Similarly the cells expressing the P2
mutant showed a 4.1 0.3-fold increase for Ser-473 and a 2.8
0.1-fold increase forThr-308 (Fig. 3B). The degree of change for
eachmutant was significantly less than that of the cells express-
ing p85-WT (p  0.001). Because IGF-I induced the Shc-medi-
ated recruitment of Grb2-associated p85 to SHPS-1 (Fig. 1A),
we compared the p85 recruitment to SHPS-1 in the cells
expressing the p85-WT and p85-P1 and -P2 mutants. Follow-
ing IGF-I stimulation the association of p85 with SHPS-1 was
significantly increased in the p85-WT cells (3.6  0.3-fold
increase; p  0.01) compared with the nonstimulated cells and
p85-P1 and p85-P2mutants. Because IGF-I-stimulated PI 3-ki-
nase activation is also required for IGF-I to stimulate cell pro-
liferation andmigration,we compared the cell proliferation and
migration responses in cells expressing wild type and the
p85-P1 and -P2mutants. Cell proliferation was increased 2.4
0.4-fold in the p85-WT-expressing cells but only 1.4  0.3-fold
in the cells expressing the P1 mutant and 1.3  0.2-fold in the
P2 mutant cells (Fig. 3D). Cell migration was also impaired
when the response of the P1 and P2mutant cells was compared
with cells expressing P85-WT (e.g. 2.5  0.2-fold for WT (p 
0.001), 1.4 0.2-fold for P1 (p 0.05), and 1.3 0.1-fold for P2
(p  0.01)) (Fig. 3E).
Effect of Disruption of Grb2 Binding to p85 Impairs AKT
Phosphorylation and Cell Migration—To confirm that Grb2
binding to p85 was required for optimum cellular responses to
IGF-I we prepared a mutant in which substitutions were intro-
duced into Grb2 to disrupt its association with p85. This
mutant, W36A/W193A, had equivalent expression of HA and
Grb2 compared with cells expressing wild type Grb2 (Fig. 4, A
and B). p85-Grb2 association was markedly impaired in the
cells expressing the W36A/W193A mutant. Following IGF-I
stimulation Grb2 binding to p85 increased 3.6  0.1-fold (n 
3, p  0.001) in cells expressing WT Grb2. In contrast cells
expressing the mutant showed a 1.8  0.1-fold increase that
FIGURE 1. Shc mediates IGF-I-stimulated PI 3-kinase/AKT activation and cell migration in VSMCs in 25 mM glucose. A, confluent Shc-WT and Shc-3F cells
were serum-starved for 14 h in DMEM-HG and then exposed to IGF-I (100 ng/ml) for 10 min. The extent of Shc phosphorylation was determined by immuno-
precipitating p52Shc and then immunoblotting with an anti-phosphotyrosine antiserum. After stripping membranes were then reprobed with anti-Shc
antibody to detect total Shc (upper panels). Similarly the lysates were immunoprecipitated with anti-Grb2 antibody and immunoblotted for p52Shc and p85.
Membranes were then stripped and reprobed with anti-Grb2 antibody to detect total Grb2 (middle panels). Further lysates were immunoprecipitated with
anti-SHPS-1 antibody and immunoblotted for p85. Subsequently the membranes were stripped and then reprobed with anti-SHPS-1 antibody to detect total
SHPS-1 (lower panels). B, VSMCs expressing Shc-WT and Shc-3F were grown to confluency in DMEM-HG and then placed in serum-free medium for 14 h.
Cultures were stimulated with or without IGF-I (100 ng/ml) for the time points indicated. Cell lysates were immunoblotted using the anti-phospho-AKT Ser-473
(top panel) and Thr-308 antibodies (middle panel). The blots were stripped and reprobed using anti--actin antibody. The bar graph shows the relative increase
in AKT phosphorylation for at least three independent experiments and two independent transductions. Error bars represent mean  S.E. **, p  0.01; *, p 
0.05. C, confluent Shc-WT and Shc-3F cell cultures were grown to confluency in DMEM-HG, and maintained in this medium containing 0.2% serum for 14 h, and
then treated with or without IGF-I (100 ng/ml) for 10 min. The anti-p85 immunoprecipitates were washed, and the pellets were incubated with PI3K and
[32P]ATP as described under “Materials and Methods.” Radiolabeled PI3K was separated by thin layer chromatography. Representative autoradiograms are
shown. The results are expressed as arbitrary scanning units, from three independent kinase assays and the error bars represent the mean  S.E. D, confluent
Shc-WT and Shc-3F cell cultures were serum-starved overnight and stimulated with IGF-I (50 ng/ml) for 10 min. The PI 3-kinase complex was immunoprecipi-
tated using anti-Grb2 antibody, and the immunoprecipitates were analyzed for kinase activity as described under “Materials and Methods.” Radiolabeled PI3K
is shown as PIP3. The bar graph shows the data expressed as arbitrary scan units (mean  S.E.) (n  3 independent experiments). ***, p  0.001 when kinase
activity in the presence of IGF-I is compared with that in nonstimulated Shc-WT cells; *, p  0.05 when the kinase activity in the presence of IGF-I is compared
between the Shc-WT and Shc-3F cells. E, migration of VSMCs expressing Shc-WT or the Shc-3F mutant. Shc-WT and Shc-3F cells were grown in 6-well dishes in
DMEM-HG containing 10% FBS. After wounding they were allowed to migrate with or without IGF-I (100 ng/ml) in medium containing 0.2% FBS for 48 h. The
total number of cells migrating past the wound line in the predetermined areas was counted, and the results shown are the mean  S.E. of three independent
experiments. *** indicates p  0.001 and * indicates p  0.05 when the number of cells migrating in response to IGF-I is compared with that in nonstimulated
cells for the Shc-WT and Shc-3F cells, respectively. Cont, control; IB, immunoblot; IP, immunoprecipitation; 3F, Shc-3F; p-AKT, phospho-AKT.
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was significantly less (p  0.05)
(Fig. 4B).
In parallel, the phosphorylation
of AKT at Thr-308 and Ser-473
were markedly attenuated in the
cells expressing the Grb2-WA
mutant as compared with cells
expressing Grb2-WT. In the
Grb2-WT cells IGF-I induced a
29.1  1.5-fold increase in AKT
(Ser-473) and a 33.9  1.9-fold
increase in AKT (Thr-308) phos-
phorylation, whereas the mutant
cells exhibited impaired responses
that were increased 10.2  0.9- and
11.9  1.1-fold, respectively (Fig.
4B). Cell proliferation increased
2.4 0.1-fold inGrb2-WT-express-
ing cells compared with 1.2  0.1-
fold forGrb2-WA (Fig. 4C). The cell
migration response was 2.1  0.1-
fold (n 3, p 0.005) after IGF-I in
WT compared with 1.5  0.3-fold
(n  3, p not significant) in cells
expressing Grb2-WA (Fig. 4D).
Effect of Hyperglycemia on IGF-I-
stimulated Shc-Grb2-p85 Associa-
tion and PI3K Activation—To
determine whether VSMCs main-
tained in normal (5 mM) glucose or
high (25 mM) glucose show changes
in signaling elements in the PI 3-ki-
nase pathway, AKT phosphoryla-
tion was analyzed. Phosphorylation
of AKT in response to IGF-I at both
serine 473 and threonine 308 was
significantly increased in 25mMglu-
cose. Phosphorylation of serine 473
increased 20.1  0.1-fold in high
glucose compared with 9.2  0.1-
fold in normal glucose (n  3, p 
0.05), and threonine 308 phospho-
rylation increased 23.2 0.1-fold in
high glucose and 10.3  0.1-fold in
normal glucose (p  0.001) follow-
ing IGF-I stimulation (Fig. 5A).
Because our previous studies had
shown that hyperglycemia led to
enhanced Shc phosphorylation and
Grb2 association with Shc following
exposure to IGF-I (3, 5) and because
Wang et al. (34) had shown a direct
association between Grb2 and p85
we determinedwhether exposure to
25mMglucosewould alterGrb2 and
p85 association. IGF-I stimulated
Grb2-p85 association (3.2 
0.1-fold), and the degree of increase
FIGURE 2. p85 polyproline region disruption attenuates Grb2-p85 association and AKT phosphoryl-
ation. A, schematic presentation of p85 subunit. The SH3 domain is located near the N terminus. The
breakpoint cluster region is flanked by two proline-rich regions, P1 and P2, on either side. Following P2 is
an SH2 domain, and another SH2 domain is located in the C-terminal region. Grb2 contains an SH2 domain
and is flanked by two SH3 domains. The proline-rich region of p85 directly associates with the SH3 domain
of the Grb2. Mutation of amino acid tryptophan at sites 36 and 193 to lysine in the SH3 domains of Grb2
impairs its association with p85 (modified from Kapeller et al. (19)). B, confluent VSMCs were serum-
starved overnight in DMEM-HG and then incubated with or without cell-permeable Grb2-p85 peptides
264 and 265 (20 g/ml) each for 2 h either individually or in combination. IGF-I (50 ng/ml) was added for
10 min. Cell lysates were immunoprecipitated with anti-Grb2 antibody and then immunoblotted with
anti-p85 antibody (first panel). Blots were stripped and reblotted with anti-Grb2 antibody (second panel).
Cell lysates were directly immunoblotted using anti-phospho-AKT Ser-473 (third panel) or Thr-308 (fourth
panel) and for total AKT (bottom panel). C, VSMCs were plated at a density of 3  104 cells/well in DMEM-
HG  2% FBS in 24-well plates and allowed to attach overnight. They were incubated with or without
cell-permeable peptides 264 and 265 (20 g/ml) together for 2 h before exposure to IGF-I (50 ng/ml) in
DMEM  0.2% platelet-poor plasma. Forty-eight hours after the addition of IGF-I, cell number was deter-
mined by trypan blue staining and counting. **, p  0.01 when the cell number in response to IGF-I is
compared with that in nonstimulated VSMCs and when the cell number in response to IGF-I is compared
with that in cells treated with both peptides. Error bars represent the mean  S.E. D, VSMCs were grown to
confluency in DMEM-HG, wounded, and allowed to migrate with or without cell-permeable peptides 264
and 265 (20 g/ml) added together for 2 h before stimulation with IGF-I (100 ng/ml) in medium containing
0.2% FBS for 48 h. The number of cells migrating in the predetermined areas was counted, and the results
shown are the mean  S.E. of three independent experiments. **, p  0.01 when the number of migrating
cells in response to IGF-I in cells is compared with that in nonstimulated VSMCs; *, p  0.05 when the cell
number in response to IGF-I is compared with that in cells treated with both peptides. IP, immunoprecipi-
tation; IB, immunoblot; Cont, control; pAKT, phospho-AKT; Pep, peptide.
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was significant (p  0.05) in cells
exposed to high glucose. In contrast
VSMCs exposed to 5 mM glucose
showed only a minimal change in
Grb2-p85 association (e.g. 1.6 0.2-
fold). When these two results were
compared, there was a significant
difference in the maximum
response (p  0.01) (Fig. 5B). As
controls, we measured the Shc
phosphorylation response, which
was significantly increased in 25mM
glucose (data not shown,) andGrb2-
Shc association (Fig. 5B). Grb2-Shc
association was increased 3.1  0.1-
fold in 25mM glucose but only 1.3
0.3-fold in 5 mM glucose (p  0.001,
n  4). The observed change in the
ability of Shc and p85 to bind to
Grb2 was not due to a change in the
total level of Shc or p85 because they
remained unchanged with or with-
out IGF-I stimulation and following
exposure to either glucose concen-
tration. To confirm that the high
glucose-mediated increase in the
Grb2-p85 association resulted in
amplification of PI3K activity and
led to an increase in AKT phospho-
rylation in response to IGF-I, PI
3-kinase was directly assessed fol-
lowing Grb2 immunoprecipitation.
IGF-I-stimulated, Grb2-associated
PI 3-kinase was increased 2.9  0.3-
fold in VSMCs cultured in 25 mM
glucose, whereas cellsmaintained in
normal glucose showed only a 1.4
0.1-fold increase (n  2) (Fig. 5C).
DISCUSSION
IGF-I stimulation of the MAPK
and PI3K/AKT pathways plays an
important role in smooth muscle
cell proliferation and migration (1).
In this study we focused on the role
of Shc and Grb2 in mediating IGF-
I-induced activation of PI3K. Our
previous studies have shown that
there is a significantly greater
increase in Shc and MAPK phos-
phorylation in response to IGF-I
when VSMCs are exposed to 25 mM
as compared with 5 mM glucose (3,
5). These studies extend those
observations to show that this
enhancement in Shc phosphoryla-
tion and subsequent Grb2 associa-
tion results in increased recruit-
FIGURE 3. Disruption of p85 binding to Grb2 attenuates IGF-I-stimulated PI 3-kinase activation, AKT
phosphorylation, and cellular responses. A, VSMCs expressing p85-WT, mutant p85-P1, and mutant p85-P2
were serum-starved overnight in DMEM-HG and analyzed for recombinant protein expression. Cell lysates
were immunoblotted using an anti-HA antibody (top) and anti-p85 antibody (bottom). B, the p85-WT and
p85-P1 and p85-P2 mutant cells were serum-starved overnight in DMEM-HG before stimulation with IGF-I (100
ng/ml) for 10 min. The lysates were immunoprecipitated with anti-Grb2 antibody and immunoblotted with
anti-p85 antibody (first panel). The blots were stripped and reprobed with anti-Grb2 antibody (second panel).
Similarly cell lysates were immunoblotted with anti-phospho-AKT Ser-473 (third panel) and Thr-308 (fourth
panel) and for total AKT (fifth panel). Lysates were also immunoprecipitated with anti-SHPS-1 antibody and
immunoblotted for p85 (sixth panel). Subsequently the membranes were stripped and then reprobed with
anti-SHPS-1 antibody to detect total SHPS-1 (bottom panel). C, confluent p85-WT and p85-P1 cell cultures were
serum-starved (in DMEM-HG, 0.2% FBS) overnight and stimulated with IGF-I (50 ng/ml) for 10 min. The PI
3-kinase complex was immunoprecipitated by using anti-p85 antibody, and the immunoprecipitates were
analyzed for kinase activity. PI 3-kinase assay was performed three times, and a representative phosphorimage
is shown. PIP3 indicates the radiolabeled phosphatidylinositol 3,4,5-trisphosphate. The origin denotes the
location where the reaction products were spotted. D, p85-WT, p85-P1, and p85-P2 cells were plated at a
density of 3  104 cells/well in DMEM-HG, 2% FBS in 24-well plates for 16 h prior to exposure to IGF-I (50 ng/ml)
in DMEM  0.2% platelet-poor plasma. After 48 h, cell number was determined by trypan blue staining and
counting. ***, p  0.001 when the cell number after exposure to IGF-I in p85-WT cells is compared with that in
nonstimulated p85-WT cells. * indicates p  0.05 and ** indicates p  0.01 when the cell number in response to
IGF-I in p85-P1 and p85-P2 mutant cells is compared with that p85-WT cells. Error bars represent the mean 
S.E. E, cell migration in response to IGF-I in VSMCs expressing p85-WT and p85-P1 mutant cells. p85 wild type
and mutant cells were grown to confluency in DMEM-HG, wounded, and allowed to migrate with or without
IGF-I (100 ng/ml) in medium containing 0.2% FBS for 48 h. The number of cells migrating in the predetermined
areas was counted, and the results shown are the mean  S.E. of three independent experiments. ***, p  0.001
when the number of p85WT cells migrating in response to IGF-I is compared with that in nonstimulated
p85-WT cells. * indicates p  0.05 and ** indicates p  0.01 when the number of cells migrating in response to
IGF-I is compared between p85-WT and p85-P1 mutant or p85-P2 mutant cells, respectively. pAKT, phospho-
AKT; IB, immunoblot; IP, immunoprecipitation; Cont, control.
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ment of Grb2-associated p85 to SHPS-1 that leads to increased
activation of PI3K in response to IGF-I. AKTactivationwas also
enhanced as were the cellular proliferation and migration
responses (Fig. 6). These results present definitive evidence that
IGF-I-stimulated Shc activation mediates the enhanced PI3K
response through an increase in Grb2-p85 binding.
Growth factor receptor phosphorylation of Shc and its sub-
sequent binding toGrb2 play important roles in various biolog-
ical responses in variety of cell types (35–38). Several studies
have shown that activation of the Shc-Grb2-Sos-MAPK path-
way is essential for an optimal mitogenic response (21, 29, 39).
Investigators have utilized expression of Shc mutants that do
not bind to Grb2 to demonstrate the importance of Shc-Grb2
association in the activation of this pathway (11–13, 29, 37, 40).
Previously we usedVSMCs expressing thismutant to show that
attenuation of Shc-Grb2 binding impairsMAPK activation and
hence reduces IGF-I-stimulated cellular proliferation (3). How-
ever, activation of PI3K is also an important signal transduction
pathway that is used by growth factor receptors (14, 15), and
previous studies from our laboratory have demonstrated that
IGF-I stimulation of PI3K in VSMCs is required for an optimal
mitogenic response and is essential for a significant increase in
cell migration (4). Therefore we sought to determine whether
Shc activation played a role in this increase in PI3K activity.
Cells expressing the Shc-3F mutant had reduced Grb2-p85
association and a significant reduction in both p85- and Grb2-
FIGURE 4. Grb2 mediates IGF-I-stimulated AKT activation, proliferation,
and migration responses in VSMCs. A, VSMCs expressing Grb2-WT and
VSMCs expressing Grb2-WA were serum-starved in DMEM-HG and analyzed
for recombinant protein expression. Cell lysates were immunoblotted using
an anti-HA antibody (top) and anti-Grb2 antibody (bottom). B, Grb2-WT- and
the mutant (Grb2-WA)-expressing cells were serum-starved in DMEM-HG
overnight, and then IGF-I (100 ng/ml) was added for 10 min. Cell lysates were
immunoprecipitated with anti-HA antibody and immunoblotted with anti-
p85 antibody (top panel). Blots were stripped and reblotted with anti-HA
antibody (second panel). In addition, cell lysates were immunoblotted with
anti-phospho-AKT antibody for Thr-308 (third panel) and Ser-473 (fourth
panel) and for total AKT (bottom panel). Each experiment was performed at
least three times. C, Grb2-WT and Grb2-WA mutant cells (3  104) were plated
in DMEM-HG  2% FBS before exposure to IGF-I (50 ng/ml) in DMEM-HG 
0.2% platelet-poor plasma. Forty-eight hours after the addition of IGF-I, cell
number was determined by trypan blue staining and counting. ***, p  0.001
when the change in cell number in response to IGF-I in Grb2-WT cells is com-
pared with that in the control or when the response to IGF-I in Grb2-WT cells
is compared with that in Grb2-WA cells. Error bars represent mean  S.E.
D, Grb2 wild type and Grb2-WA mutant cells were grown to confluency in
DMEM-HG, wounded, and allowed to migrate with or without IGF-I (100
ng/ml) in DMEM-HG containing 0.2% FBS for 48 h. The number of cells migrat-
ing in the predetermined areas was counted, and the results shown are the
mean  S.E. of three independent experiments. **, p  0.01 when the num-
ber of Grb2-WT cells after IGF-I is compared with that in nonstimulated con-
trol; *, p  0.05 when the number of migrating cells after IGF-I is compared
between Grb2-WT and Grb2-WA cells. IP, immunoprecipitation; IB, immuno-
blot; pAKT, phospho-AKT; Cont, control.
FIGURE 5. Hyperglycemia increases IGF-I-mediated AKT activation and
Shc-Grb2-p85 association in porcine VSMCs. A, quiescent VSMC cultures
were incubated in serum-free medium containing 5 (NG) or 25 (HG) mM glu-
cose overnight. Cells were stimulated with IGF-I (100 ng/ml) for 10 min. After
cell lysis aliquots containing equal amounts of protein were separated
directly by SDS-PAGE and immunoblotted (IB) with anti-phospho-AKT-spe-
cific antibodies for phosphorylation of threonine 308 (upper panel) and serine
473 (middle panel) and also for total AKT (bottom panel). B, the extent of Shc
association with Grb2 was determined by immunoprecipitating (IP) cell
lysates with an anti-Grb2 antibody and then immunoblotting with an anti-
Shc antibody. Similarly the extent of the p85 association with Grb2 was deter-
mined by immunoprecipitation using an anti-Grb2 antibody and then immu-
noblotting with an anti-p85 antibody. Membranes were then stripped and
reprobed with anti-Grb2 antibody to detect total Grb2 in each sample. In
addition, cell lysates were immunoblotted with anti-p85 (fourth panel) and
anti-p52Shc antibodies (fifth panel). The blots were stripped and reprobed
using anti--actin antibody to control for differences in loading (bottom
panel). All experiments were repeated at least three times. Error bars repre-
sent mean  S.E. **, p  0.01. C, VSMCs cultured in normal glucose or high
glucose were serum-starved (0.2% FBS) and stimulated with IGF-I (50 ng/ml)
for 10 min. The PI 3-kinase complex was immunoprecipitated by using anti-
Grb2 antibody, and the immunoprecipitates were analyzed for kinase activ-
ity. The PI 3-kinase assay was performed twice, and a representative phospho-
rimage is shown. PIP3 indicates the radiolabeled phosphatidylinositol 3,4,5-
trisphosphate. p-AKT, phospho-AKT; Cont, control.
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associated PI3K activation following IGF-I stimulation. This
finding suggested that Shc mediated Grb2 availability for bind-
ing to p85 and that Grb2 binding regulated the ability of p85 to
activate PI3K. Because IGF-I addition resulted in major
increases in Grb2-p85 association we blocked the Grb2-p85
interaction using two approaches (e.g. cell-permeable blocking
peptides and mutagenesis). Both approaches resulted in Grb2-
p85 disruption and more importantly a reduction in the ability
of IGF-I to activate PI3K. Therefore we conclude that this Shc-
facilitated increase in Grb2-p85 association is required for
enhanced PI3K activation in response to IGF-I.
Our studies show that the Grb2-p85 interaction is mediated
through interaction of the SH3 domains of Grb2 and proline-
rich regions in p85. Mutagenesis of the proline-rich regions
resulted in decreased PI-3K and AKT activation in response to
IGF-I. Further our studies confirmed the importance of this
interaction by expressing a Grb2 mutant (W36A/W193A) that
could not bind to p85 and showing that this resulted in a similar
attenuation of activity. Prior studies have reported that proline-
rich sequences in p85 interacted with SH3 domains in Abl, Lck,
Lyn, and Fyn (19, 20). Pleiman et al. (20) showed that addition
of synthetic peptides with sequences derived from the SH3
domains of Fyn and Lyn that have sequences that are similar to
the SH3 domain of Grb2 resulted in a 5–7-fold enhancement of
PI3K activity in vitro. They also showed that a cell-permeable
synthetic peptide containing the region of p85 (amino acids
80–104) that interacts withGrb2 inhibited PI3K activation in B
cells. The importance of Grb2-p85 association for PI3K enzy-
matic activation was reported byWang et al. (34) who demon-
strated that p85 could bind directly to Grb2 both in vitro using
purified proteins and in NIH-3T3 cells. In addition, they dem-
onstrated that followingGrb2-p85 association the p110 subunit
of PI3K remained associated with p85 and that the complex
retained full catalytic activity.
In terms of the relative activity of the two sites, our findings
show that the P2 site appears to be more important for Grb2
binding to p85 and for PI3K activation in response to IGF-I.
Other studies have shown a relatively greater effectwhen the P1
site is altered (20, 34). This difference could be explained by
differences in the specificity of various SH3domains for distinct
polyproline sequences or by the fact that different test systems
were utilized to compare activity. Because the proline-rich
regions of p85 bind to both the internal SH3 domain in p85 and
to other proteins with SH3 domains, the normal regulation of
PI3K activation has been suggested to involve competition
between the exogenous SH3 domains and the internal SH3
domain of p85 thus leading to an alteration in the interaction
between p85 and p110 (41). Because the interaction of SH3
domain ofGrb2with p85 increases PI3K activation it is possible
that Grb2 binding may function to alter the p85-p110 interac-
tion thus relieving the p85 constraint of p110 activity.
Previously C-terminal SH3 domain of Grb2 binding to Gab1
(42) has been shown to result in tyrosine phosphorylation of
Gab1 that generates binding sites for p85 thereby activating
PI3K (43). Similarly a complicated signaling scaffold formed by
three adaptors, Shc, Grb2, and Gab2, was shown to mediate
recruitment of PI3K to the plasma membrane in cells activated
by cytokines such as interleukin 3 and interleukin 2 (21, 44).
However, our prior studies have shown that VSMCs do not
utilize Gab2 for p85 or p110 recruitment.3 In contrast our prior
studies suggest that the transmembrane protein SHPS-1 serves
as a scaffold for p85p110 complex assembly (30). Following its
tyrosine phosphorylation in response to IGF-I, SHPS-1 func-
tions as a scaffold for assembly of a complex containing SHP-
2c-SrcShc and Grb2 (3, 30, 45). Our results show that p85
recruitment to SHPS-1 is impaired in VSMCs expressing the
Shc mutant and in p85 mutant cells. This suggests that in
VSMCsGrb2 recruitment to SHPS-1 via Shc functions to local-
ize p85 to this SHPS-1 complex. This is supported by a recent
report that phosphotyrosyl peptides derived from B and T lym-
phocyte attenuator, which has strong sequence homology with
SHPS-1, associated directly with Grb2 and recruited p85
through Grb2 association (46).
Although only a small fraction of Grb2 is associated with p85
and vice versa, the interaction presents intriguing possibilities
for linking PI3K activation to growth factor receptors, such as
the IGF-I receptor, that lack the ability to bind PI3K directly.
This dependence upon assembly of a ShcSHPS-1Grb2 com-
plex to achieve full PI3K activation suggests that recruitment of
p85p110 to the membrane is also important for activation by
IGF-I.
Exposure of VSMCs to hyperglycemia modifies the mito-
genic response to several growth factors including IGF-I (5, 47,
48). In VSMCs hyperglycemia results in increased proliferation
and migration, and these responses are associated with
enhancedMAPK activation (5). Similar observations have been
reported in streptozotocin-induced diabetic rats that show an
3 Y. Ling and D. R. Clemmons, unpublished data.
FIGURE 6. IGF-I-induced activation of PI 3-kinase/AKT and MAPK path-
ways in VSMCs. VSMCs maintained in HG conditions upon IGF-I stimulation
show enhanced activation of the MAPK and PI3K/AKT pathways leading to
increased proliferation and migration compared with cells grown in NG. IGF-
I-stimulated Shc mediates activation of MAPK via Grb2-Sos binding. In HG
conditions Shc-mediated, Grb2-associated p85 recruitment to SHPS-1 acti-
vates the PI3K/AKT pathway increasing VSMC proliferation and migration in
response to IGF-I stimulation.
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increase in Shc phosphorylation and Grb2 association with
insulin stimulation (49). Our studies have shown that this
enhanced MAPK activity is dependent upon increased Shc
tyrosine phosphorylation and Grb2 association (3, 5). The cur-
rent results suggest that high glucose is also inducing enhanced
p85-Grb2 association in response to IGF-I thus leading to
enhanced PI3K activation. In VSMCsmaintained in normogly-
cemic conditions it is well established that IRS-1 mediates the
PI3K activation in response to insulin or IGF-I (50). IRS-1 con-
tains several tyrosine phosphorylation sites and six YMXM
motifs. Upon stimulation tyrosine phosphorylated YXXM
motifs associate with SH2 domains of p85 (51), and the engage-
ment of p85 SH2 domain relieves the p85-mediated inhibition
of p110 thus increasing the enzymatic activity of p110 (17).
However, with hyperglycemia there is amajor decrease in IRS-1
tyrosine phosphorylation (5, 52, 53), and hyperglycemia medi-
ates IRS-1 degradation (23, 54), which leads to a decrease in
IRS-1-mediated PI3K activation (8, 23, 25). IRS-1 repression
has been shown to induce a substantial increase in Shc expres-
sion and its tyrosine phosphorylation in response to insulin,
and it has been proposed that in the absence of IRS-1 enhanced
Shc phosphorylation could represent an alternative pathway to
transduce insulin signaling (55, 56). Additionally IGF-I-in-
duced tyrosine phosphorylation of IRS-1 has been shown to be
decreased by overexpression of Shc-WT inL6myoblasts, and in
that system IRS-1-associated p85 and PI3K activation were also
reduced (10). Because Shc competes with IRS-1 for the same
limited pool of Grb2 for binding (57), the preferential increase
in Shc-mediated signaling in VSMCs in high glucose in
response to IGF-I would be predicted to further reduce the
amount of Grb2 that is bound to IRS-1. Under these conditions
the increase in PI3K activation that occurs in response to IGF-I
inVSMCs appears to be directly dependent upon Shc-mediated
Grb2-p85 association.
In summary, we conclude that IGF-I-induced Shc enhances
the activation of the PI3K pathway by increasing Grb2-p85
association leading tomembrane recruitment. This in turn aug-
ments AKT signaling as well as proliferation and migration. In
hyperglycemic conditions, preferential Shc activation enhances
the PI3K/AKT signaling pathway that leads to vascular dys-
function suggesting a possible role in atherosclerosis.
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